secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2021-08-03T23:59:59+00:00
Accession:  0001104659-21-099173
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa posts Q2 ARCALYST revenue of $7.7M; net loss $41.6M; guides Q3 rev $9-10M
--------------------------------------------------------------------------------

- ARCALYST net revenue $7.7M in first quarter of sales (April 1 launch); >100 physicians prescribed in Q2.
- Net loss $41.6M vs $37.5M YoY; operating expenses $48.3M (incl $5.7M stock comp).
- Cash and investments $225.9M, no debt; expects to fund operations into 2023.
- Q3 2021 ARCALYST revenue guidance $9-10M; pipeline: mavrilimumab Ph3 data Q1 2022, KPL-404 Ph2 start Q4 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465921099173/0001104659-21-099173-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465921099173/tm2123663d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-099173

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer